FINANCIAL SUMMARY - FOURTH QUARTER 2020
“It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking.
The Danish Patent Office has granted Qlife patent number DK180348 B1 for its biomarker detection unit.
The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market.
Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short.
Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark.
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for th
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high preci
Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants
FINANCIAL SUMMARY - THIRD QUARTER 2020
In parallel to the ongoing process of preparing and putting together the dossier for the CE-mark, Qlife has submitted an application for placing the product on the market at this stage, as it offer
The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.
Information regarding the coronavirus
Qlife was originally expecting CE-mark for the product in October, but the company is now expecting approval within the coming two to three months.
Due to the increasing of infectious rates over the past few weeks, it has been agreed that Qlife will be handling all testing for COVID-19 for professional handball in Denmark.
FINANCIAL SUMMARY – SECOND QUARTER 2020
In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen.
Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD.
Jakob has extensive experience from international sales and business development within MedTech and healthcare and brings an excellent record of results and achievements in complex and competitive
In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22.
"Henrik Ljung brings broad experience to Qlife from financial reporting, IR, business control, finance management and corporate governance, all with a focus on fast-growing companies in the ea
KMD and Qlife has entered an agreement with Badmint
Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment
The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months.
Resolution on adoption of accounts and allocation of the company’s result
FINANCIAL SUMMARY FIRST QUARTER 2020
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.
Information regarding the coronavirus
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:
Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.
The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.
The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November.
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.
Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment
In the enclosed Newsletter you will find updated information about our operations and preparations for the next steps.
Biomarkers in our blood can show us a lot about our health, the development of a disease or how tough we have been to our body during a workout.
Every day, the Danish healthcare system produces a large amount of data.
Six interesting companies in total will present their businesses.